Vilon

Vilon is the dipeptide Lys-Glu, abbreviated KE. It is not dilysine (Lys-Lys). The selected literature includes human adjunct-treatment reports as well as animal and cell experiments, but it does not establish a reliable clinical benefit-risk profile or human rejuvenation effect. PMID:17152731 PMID:37782636

Evidence scope

This bibliography selects 25 publications: five human-containing reports, 17 preclinical experimental reports and three review or synthesis documents. Twenty-two have PubMed identities; three are publisher PDFs. Human donor cells remain preclinical material, and mixed-peptide experiments are not isolated Vilon efficacy studies. Publication counts are not counts of independent trials or unique participants. Some reports may reuse cohorts; no combined participant total is asserted. This is a bounded selection, not a complete Vilon literature census.

Clinical certainty has not been formally graded. Clinical benefit remains very uncertain. Numerical and legacy scores are withheld pending full reassessment; discovery of human reports does not itself justify a score increase. Open-access coverage for the complete selection is unknown.

Human reports: findings and substantial limitations

Type 1 diabetes: Two older reports describe Vilon added to complex treatment. The 2006 record is indexed as a Randomized Controlled Trial, but its inspected abstract does not describe the randomization method, concealment, blinding or sample size. It reports coagulation and fibrinolysis findings, with a less pronounced response in elderly patients with severe disease. The 2007 report discusses hemostasis, immune markers and insulin requirements without usable numerical effect estimates or an adverse-event denominator. These observations do not establish prevention of thrombosis or mortality, and they do not provide guidance for changing insulin treatment. The two publications have unknown cohort overlap and are not proven independent replications. PMID:17152731 PMID:18306698

Colorectal cancer: A 2005 report, indexed as a Controlled Clinical Trial, describes adjunct Vilon in complex radical treatment of elderly patients with stage III colorectal cancer. Its abstract offers preliminary survival and complication claims without event counts, comparator details, reliable effect estimates or uncertainty. It cannot establish the incremental effect of Vilon separately from the accompanying cancer treatments; randomization is not established by that indexing. PMID:16075684

Post-infection convalescence: A November 10, 2022 Mini Review, The Effect of Short Peptides on Increasing the Reserve Capacity of the Human Body, contains a reported 520-person Vilon account with 276 assigned to Vilon and 244 to placebo. Calling the article a review does not erase this human administration account, but stated random assignment is not verified trial conduct. Allocation, blinding, product composition, background care, participant flow and analysis methods are inadequately characterized. Its immune-marker table marks within-group changes from baseline, not a between-arm treatment effect; the separate symptom table includes control comparisons but lacks adequate validation and bias safeguards. An unexplained normalization percentage is not accepted as an efficacy estimate. The preceding Epitalon cohort is a different intervention. Publisher report, EC Clinical and Medical Case Reports 5.11 (2022):98–105

Atrophic gastritis: Prospects for the Use of Dipeptide in Patients with Chronic Atrophic Gastritis, published May 23, 2022, describes 98 people allocated 49/49 in an open prospective study using an envelope method. Vilon was adjunctive to standard eradication treatment, not tested as monotherapy. Envelope concealment, participant flow and product characterization remain insufficiently documented. Gastric pH changes were not statistically significant in either arm. Without numerical pH results and precision, that null finding establishes neither restoration of acidity nor equivalence. The symptom table’s significance marks compare with baseline, not directly between arms. Publisher report, EC Gastroenterology and Digestive System 9.6 (2022):01–05

That gastritis report also contains unresolved symptom-reporting inconsistencies. Under its stated 0–3 scale and 49-person denominator, 33 complete appetite resolutions would permit a maximum final mean of 48/49, below the printed 1.11; 27 fullness resolutions would permit a maximum of 66/49, below the printed 1.88. These conditional inconsistencies require clarification, not guessed corrected values or assumptions about their cause. No response percentage is accepted here. The gastritis and convalescence publications describe distinct study accounts, but do not establish 618 unique people or independent replication. Gastritis report Convalescence report

Dental review context: The May 22, 2025 review Prospects for the Use of Short Peptides in Dentistry summarizes older Vilon-related material; it is not a new clinical trial. Its 269-person account depends on incompletely separated earlier Vilon and Epithalamin-plus-Vilon references whose originals remain unread. A 615-person mixed-peptide gel account and a 118-person Thymogen/Epithalamin account are not native-Vilon cohorts. Two indexed review/synthesis publications likewise discuss multiple bioregulators rather than adding independently verified Vilon trials. Publisher review, EC Clinical and Medical Case Reports 8.6 (2025):01–06 PMID:24003726 PMID:32362097

Safety and conflicting animal findings

Human safety remains insufficiently characterized. A statement that no adverse effects were identified in a report is not structured adverse-event surveillance or proof of long-term safety. The older abstracts lack usable safety denominators, and the publisher accounts do not provide adequate systematic ascertainment. PMID:17152731 PMID:16075684 Convalescence report Gastritis report

Animal findings point in different directions. A female CBA mouse study reported longer lifespan and fewer spontaneous neoplasms, but no effect on estrous or free-radical measures. In contrast, a female HER2/neu mouse study reported increased mammary-cancer incidence, shorter tumour latency and more cumulative tumours with Vilon. Favorable Epitalon findings in that experiment belong to another peptide. These results do not predict a human cancer effect, but they preclude a blanket benign or anticancer characterization. PMID:11140587 PMID:12209581

A Lewis lung carcinoma mouse experiment reported increased survival with Vilon alone but reduced survival with synchronous Vilon and cyclophosphane. Separate rat-explant results in the same report are not the mouse survival endpoint. This is model-specific combination evidence, not a quantified human interaction or an administration recommendation. PMID:14743610

Other reports describe reduced chemically induced bladder tumours in rats and reduced carcinogen-associated tumours in mice. In the latter, the reported proportions are restricted to animals surviving until first tumour detection, not a verified whole-cohort analysis. Related animal programmes may overlap, so distinct publication identities do not prove independent replication. PMID:11586406 PMID:16308980

Mechanisms: measured models, not clinical regeneration

Mouse thymocyte experiments examined proliferation and sphingomyelinase signaling. Human thymic-cell cultures examined nucleolar-organizer proteins and proliferative changes. Neither is evidence of a regenerated thymus in treated people. A separate microarray study measured mouse-heart gene expression, including a Vilon/Epithalon combination arm, rather than thymic architecture. Rat hypothalamic c-Fos and IL-2 patterns depended on stress and adaptation; they do not establish a general increase in peripheral IL-2. PMID:12420072 PMID:15455093 PMID:12360356 PMID:18264770

Cultured old-donor lymphocytes showed selective chromatin changes; the Vilon report explicitly excludes pericentromeric structural heterochromatin decondensation. Broader multi-peptide chromatin descriptions do not erase that exception. The 2023 lymphocyte paper is also a culture study, not a human rejuvenation trial. PMID:15105581 PMID:33526740 PMID:37042594

In embryonic mesenchymal-cell aging models, KE increased FOXO1 expression in stationary aging but not passage aging, and stimulated NFκB gene expression. These directions cannot all be labeled anti-inflammatory benefit. A 2023 mesenchymal-cell report measured SIRT1/PARP1/PARP2 changes and included DNA-docking hypotheses. A thymic-cell study measured mitochondrial staining and ribosomal-protein expression, not restored mitochondrial function in treated people. PMID:32399807 PMID:37782636 PMID:33342107

The periodontal-ligament stem-cell paper tested several peptides, including KE, but its abstract highlights KED and a mixture. Those findings cannot establish KE-alone neuronal differentiation. PMID:30791821

The 2022 inflammatory-cell paper tested Vilon separately as P2 among five preparations, using leukemia-derived THP-1 cells, macrophage differentiation and endothelial-cell adhesion assays. Vilon alone had little ERK1/2 modulation; inflammatory stimulation changed responses. Reported macrophage TNF/IL-6 and adhesion reductions are culture findings, while Chonluten-specific monocyte results belong to another preparation. The nuclear microscopy tracks STAT1 protein, not directly labeled Vilon. The statistical description gives three independent experiments and mean±SD; it does not establish a human sample size. Italian and Russian affiliations contradict a Russian-only research description but do not prove independent replication. PMID:35408963

Identity, registration and unanswered questions

The similarly named registry result NCT02580799 is a non-interventional HER2 pathology-sample concordance study with no Vilon intervention; it supplies no peptide trial evidence. A query-specific exclusion is not proof that no Vilon trial exists elsewhere. Registry record

The research inventory separately holds PMID29322736 because its title and abstract conflict, and excludes a ViLoN network algorithm. Neither is included in the 25-publication selection. No preparation-specific molecular mass, purity, absorption or clinical availability is inferred from the KE identity. No DOI is printed in the three inspected publisher PDFs; no external DOI-registration census was performed, and none is invented here.

Are there human studies? Yes: this selection includes five human-containing reports, with substantial methods, provenance, product and reporting limitations. They are not five independently authenticated trials and do not establish an immune-support or rejuvenation indication.

Are combinations safe or beneficial? That is not established for people by this review. Animal combination experiments exist, including an adverse survival finding; shared mechanisms or different tissue labels do not establish human compatibility. PMID:12360356 PMID:14743610

No complete regulatory or community-use inventory was assessed. Author-reported supplement notification or free-sale statements are not independently verified drug approvals. Research-only catalogue framing does not establish a legal classification in every jurisdiction. Remaining needs include older clinical full methods, cohort provenance, reliable outcome estimates and human safety ascertainment.

This dossier is educational research information, not medical advice or instructions for obtaining or using a peptide.